Spyglass Pharma, Inc. (NASDAQ:SGP - Get Free Report) Director Ra Capital Management, L.P. bought 1,000 shares of Spyglass Pharma stock in a transaction dated Monday, November 16th. The stock was acquired at an average cost of $32.43 per share, for a total transaction of $32,430.00. Following the completion of the transaction, the director directly owned 5,967,439 shares in the company, valued at approximately $193,524,046.77. This trade represents a 0.02% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Spyglass Pharma Price Performance
NASDAQ SGP traded down $1.75 during trading hours on Wednesday, reaching $29.68. 95,000 shares of the company's stock traded hands, compared to its average volume of 109,105. Spyglass Pharma, Inc. has a 52-week low of $17.06 and a 52-week high of $39.92. The firm has a market cap of $993.09 million and a PE ratio of -3.84. The firm has a 50-day simple moving average of $28.90 and a 200 day simple moving average of $24.90.
Spyglass Pharma (NASDAQ:SGP - Get Free Report) last announced its quarterly earnings data on Thursday, November 12th. The company reported ($0.73) earnings per share for the quarter, missing analysts' consensus estimates of ($0.66) by ($0.07). Sell-side analysts forecast that Spyglass Pharma, Inc. will post -2.77 EPS for the current fiscal year.
Hedge Funds Weigh In On Spyglass Pharma
A number of hedge funds have recently added to or reduced their stakes in SGP. Bank of New York Mellon Corp bought a new stake in shares of Spyglass Pharma in the 2nd quarter worth $533,000. Bank of America Corp DE bought a new position in shares of Spyglass Pharma during the first quarter valued at $726,000. The Manufacturers Life Insurance Company bought a new position in shares of Spyglass Pharma during the first quarter valued at $308,000. First Light Asset Management LLC purchased a new stake in shares of Spyglass Pharma during the first quarter valued at $9,716,000. Finally, Affinity Asset Advisors LLC purchased a new stake in shares of Spyglass Pharma during the first quarter valued at $6,478,000.
Analyst Ratings Changes
A number of research analysts have issued reports on the company. UBS Group reiterated a "buy" rating on shares of Spyglass Pharma in a research note on Monday, October 5th. HC Wainwright raised their price target on Spyglass Pharma from $37.00 to $43.00 and gave the company a "buy" rating in a report on Thursday, November 12th. Stifel Nicolaus raised their price target on Spyglass Pharma from $42.00 to $44.00 and gave the company a "buy" rating in a report on Friday, November 13th. Raymond James Financial assumed coverage on Spyglass Pharma in a research report on Friday, August 14th. They issued an "outperform" rating and a $39.00 price target for the company. Finally, Citigroup upped their price target on shares of Spyglass Pharma from $42.00 to $45.00 and gave the stock a "buy" rating in a research note on Friday, November 13th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $45.83.
View Our Latest Report on SGP
Spyglass Pharma Company Profile
(
Get Free Report)
SpyGlass Pharma is a clinical-stage ophthalmology company developing sustained-release drug delivery systems for chronic eye diseases. Its research is focused on reducing reliance on patients' regular use of eye drops. The company's lead program is a bimatoprost drug delivery system being developed to treat glaucoma and ocular hypertension. Bimatoprost is a medication used to lower eye pressure, and SpyGlass is studying a delivery approach intended to provide treatment over an extended period. SpyGlass Pharma's work centers on advancing this ophthalmic delivery platform and its lead program through clinical development.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Spyglass Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Spyglass Pharma wasn't on the list.
While Spyglass Pharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.